TABLE 4.
Univariate and multivariate analyses of PFS and OS in the EGFR L858R subtype and 19 del subtype
| PFS analysis | OS analysis | |||||||
|---|---|---|---|---|---|---|---|---|
| Univariate | Multivariate | Univariate | Multivariate | |||||
| HR (95% CI) | p value | HR (95% CI) | p value | HR (95% CI) | p value | HR (95% CI) | p value | |
| (A) L858R subtype | ||||||||
| Age (<74/≧75) | 1.01 (0.72–1.41) | 0.972 | 0.97 (0.68–1.37) | 0.846 | 0.77 (0.54–1.10) | 0.152 | 0.77 (0.53–1.13) | 0.186 |
| Sex (male/female) | 1.22 (0.89–1.68) | 0.219 | 1.23 (0.80–1.89) | 0.355 | 1.39 (0.99–1.96) | 0.056 | 1.48 (0.94–2.32) | 0.087 |
| Stage (relapse, IIIB/IV) | 0.54 (0.39–0.76) | <0.001 | 0.47 (0.32–0.69) | <0.001 | 0.75 (0.52–1.09) | 0.130 | 0.67 (0.44–0.99) | 0.046 |
| PS (0,1/2) | 0.56 (0.38–0.82) | 0.003 | 0.45 (0.30–0.68) | <0.001 | 0.54 (0.35–0.82) | 0.004 | 0.45 (0.29–0.69) | <0.001 |
| Smoke (former, current/never) | 1.23 (0.91–1.67) | 0.183 | 1.08 (0.72–1.63) | 0.700 | 1.22 (0.88–1.70) | 0.229 | 1.08 (0.70–1.66) | 0.733 |
| TKI (first‐, second‐gen/osimertinib) | 1.29 (0.78–2.14) | 0.323 | 1.38 (0.83–2.30) | 0.218 | 1.27 (0.61–2.65) | 0.526 | 1.19 (0.57–2.49) | 0.646 |
| History of CRT (yes/no) | 0.77 (0.24–2.42) | 0.654 | 1.65 (0.48–5.66) | 0.430 | 1.01 (0.32–3.19) | 0.984 | 1.64 (0.48–5.62) | 0.433 |
| MVI (yes/no) | 1.18 (0.52–2.67) | 0.691 | 0.86 (0.37–1.99) | 0.730 | 1.79 (0.79–4.06) | 0.167 | 1.22 (0.52–2.86) | 0.647 |
| CVD (yes/no) | 0.92 (0.57–1.47) | 0.721 | 1.27 (0.76–2.12) | 0.352 | 1.56 (0.97–2.51) | 0.065 | 1.69 (1.00–2.86) | 0.052 |
| Bloody sputum (yes/no) | 1.62 (1.01–2.59) | 0.044 | 1.78 (1.09–2.90) | 0.021 | 1.55 (0.94–2.55) | 0.082 | 1.94 (1.14–3.30) | 0.015 |
| (B) 19 del subtype | ||||||||
| Age (<74/≧75) | 1.10 (0.81–1.49) | 0.535 | 1.05 (0.77–1.43) | 0.746 | 0.72 (0.52–1.00) | 0.047 | 0.66 (0.47–0.93) | 0.018 |
| Sex (male/female) | 1.45 (1.09–1.94) | 0.012 | 1.22 (0.82–1.83) | 0.326 | 1.64 (1.20–2.23) | 0.002 | 1.47 (0.92–2.34) | 0.102 |
| Stage (relapse, IIIB/IV) | 0.60 (0.43–0.83) | 0.002 | 0.60 (0.41–0.86) | 0.006 | 0.67 (0.47–0.95) | 0.025 | 0.76 (0.51–1.12) | 0.167 |
| PS (0,1/2) | 0.66 (0.43–1.00) | 0.051 | 0.71 (0.45–1.13) | 0.146 | 0.48 (0.31–0.75) | 0.001 | 0.48 (0.30–0.75) | 0.002 |
| Smoke (former, current/never) | 1.34 (1.01–1.78) | 0.040 | 1.17 (0.79–1.73) | 0.425 | 1.46 (1.07–1.98) | 0.017 | 1.28 (0.80–2.04) | 0.302 |
| TKI (first‐, second‐generation/osimertinib) | 1.44 (0.76–2.74) | 0.262 | 1.69 (0.87–3.28) | 0.124 | 1.17 (0.47–2.92) | 0.734 | 1.31 (0.52–3.29) | 0.571 |
| History of CRT (yes/no) | 1.35 (0.70–2.53) | 0.375 | 1.68 (0.80–3.54) | 0.170 | 1.08 (0.55–2.11) | 0.834 | 1.14 (0.52–2.53) | 0.738 |
| MVI (yes/no) | 1.96 (1.00–3.85) | 0.051 | 1.58 (0.74–3.38) | 0.241 | 1.69 (0.86–3.32) | 0.126 | 1.51 (0.71–3.22) | 0.282 |
| CVD (yes/no) | 1.94 (1.14–3.31) | 0.015 | 1.47 (0.84–2.59) | 0.181 | 1.86 (1.09–3.18) | 0.022 | 1.10 (0.62–1.96) | 0.731 |
| Bloody sputum (yes/no) | 1.63 (1.09–2.44) | 0.017 | 1.18 (0.76–1.82) | 0.467 | 1.64 (1.07–2.52) | 0.024 | 1.42 (0.88–2.26) | 0.148 |
Abbreviations: Bloody sputum, tumor exposure in the bronchus or producing bloody sputum; CI, confidence interval; CRT, chemoradiotherapy; CVD, cardiovascular disease; first‐, second‐gen, first‐ and second‐generation EGFR‐TKI; HR, hazard ratio; MVI, major vessel infiltration; PFS, progression‐free survival; PS, performance status; TKI, tyrosine kinase inhibitor.
Bold values are p <0.05, which is statistically significant.